133 related articles for article (PubMed ID: 37699070)
1. Incidence and predisposing factors for flucloxacillin-related hepatotoxicity in children.
Coombs S; Pittet LF; Tang K; Gwee A
J Antimicrob Chemother; 2023 Nov; 78(11):2667-2671. PubMed ID: 37699070
[TBL] [Abstract][Full Text] [Related]
2. Incidence of amoxycillin-clavulanic acid associated hepatotoxicity in an Australian children's hospital.
Eldredge JA; Pittet LF; Gwee A
J Antimicrob Chemother; 2024 Mar; 79(3):589-594. PubMed ID: 38297994
[TBL] [Abstract][Full Text] [Related]
3. Frequency of drug-induced liver injury in children receiving anti-staphylococcal penicillins.
Tang K; Coombs S; Gwee A
J Antimicrob Chemother; 2022 Nov; 77(12):3221-3230. PubMed ID: 36203386
[TBL] [Abstract][Full Text] [Related]
4. Quantification of the risk of liver injury associated with flucloxacillin: a UK population-based cohort study.
Wing K; Bhaskaran K; Pealing L; Root A; Smeeth L; van Staa TP; Klungel OH; Reynolds RF; Douglas I
J Antimicrob Chemother; 2017 Sep; 72(9):2636-2646. PubMed ID: 28859440
[TBL] [Abstract][Full Text] [Related]
5. Drug-induced liver injury in the Australian setting.
Sistanizad M; Peterson GM
J Clin Pharm Ther; 2013 Apr; 38(2):115-20. PubMed ID: 23350857
[TBL] [Abstract][Full Text] [Related]
6. Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens.
Denton CC; Rawlins YA; Oberley MJ; Bhojwani D; Orgel E
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29218844
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial.
Ibrahim LF; Hopper SM; Orsini F; Daley AJ; Babl FE; Bryant PA
Lancet Infect Dis; 2019 May; 19(5):477-486. PubMed ID: 30853250
[TBL] [Abstract][Full Text] [Related]
8. Cholestatic hepatitis associated with flucloxacillin.
Derby LE; Jick H; Henry DA; Dean AD
Med J Aust; 1993 May; 158(9):596-600. PubMed ID: 8479374
[TBL] [Abstract][Full Text] [Related]
9. Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia.
Yang JJ; Huang CH; Liu CE; Tang HJ; Yang CJ; Lee YC; Lee KY; Tsai MS; Lin SW; Chen YH; Lu PL; Hung CC
PLoS One; 2014; 9(9):e106141. PubMed ID: 25184238
[TBL] [Abstract][Full Text] [Related]
10. Flucloxacillin-Induced Hepatotoxicity - Association with HLA-B*5701.
Teixeira M; Macedo S; Batista T; Martins S; Correia A; Matos LC
Rev Assoc Med Bras (1992); 2020; 66(1):12-17. PubMed ID: 32130375
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury.
García-Cortés M; Lucena MI; Pachkoria K; Borraz Y; Hidalgo R; Andrade RJ;
Aliment Pharmacol Ther; 2008 May; 27(9):780-9. PubMed ID: 18284654
[TBL] [Abstract][Full Text] [Related]
12. Flucloxacillin associated neutropenia in children treated for bone and joint infections.
van den Boom J; Kristiansen JB; Voss LM; Stott NS
J Paediatr Child Health; 2005; 41(1-2):48-51. PubMed ID: 15670224
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for development of flucloxacillin associated jaundice.
Fairley CK; McNeil JJ; Desmond P; Smallwood R; Young H; Forbes A; Purcell P; Boyd I
BMJ; 1993 Jan; 306(6872):233-5. PubMed ID: 8443520
[TBL] [Abstract][Full Text] [Related]
14. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland.
Björnsson ES; Bergmann OM; Björnsson HK; Kvaran RB; Olafsson S
Gastroenterology; 2013 Jun; 144(7):1419-25, 1425.e1-3; quiz e19-20. PubMed ID: 23419359
[TBL] [Abstract][Full Text] [Related]
15. Isoniazid-induced hepatotoxicity in children with latent tuberculosis infection.
Devrim İ; Devrim F; Bayram N; Aktürk H; Aksay A; Can D; Apa H
Minerva Pediatr (Torino); 2021 Apr; 73(2):184-187. PubMed ID: 26377643
[TBL] [Abstract][Full Text] [Related]
16. Alanine transaminase and hemoglobin appear to predict the occurrence of antituberculosis medication hepatotoxicity; findings and implications in Botswana.
Kesenogile B; Godman B; Rwegerera GM
Expert Rev Anti Infect Ther; 2021 Mar; 19(3):379-391. PubMed ID: 32909487
[TBL] [Abstract][Full Text] [Related]
17. Hepatotoxicity from isoniazid and rifampin among children treated for tuberculosis.
O'Brien RJ; Long MW; Cross FS; Lyle MA; Snider DE
Pediatrics; 1983 Oct; 72(4):491-9. PubMed ID: 6604257
[TBL] [Abstract][Full Text] [Related]
18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients.
Ohkawa K; Hashiguchi M; Ohno K; Kiuchi C; Takahashi S; Kondo S; Echizen H; Ogata H
Clin Pharmacol Ther; 2002 Aug; 72(2):220-6. PubMed ID: 12189369
[TBL] [Abstract][Full Text] [Related]
20. Flucloxacillin and cholestatic hepatitis.
Jick H; Derby LE; Dean AD; Henry DA
Med J Aust; 1994 Apr; 160(8):525. PubMed ID: 8170433
[No Abstract] [Full Text] [Related]
[Next] [New Search]
